Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Series
Current Oncology · 27.05.2026 · 33 (6) · 311
DOI: 10.3390/curroncol33060311 ↗Kurz gefasst
Fallbericht in der Zeitschrift Current Oncology, online erschienen am 27.05.2026. Verfasst von Po-Tsen Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University…. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer is a leading cause of global cancer mortality, with EGFR mutations serving as a primary therapeutic target. Although EGFR tyrosine kinase inhibitors (TKIs) are initially effective, acquired resistance inevitably develops. While ROS1 rearrangements are well-known baseline drivers, they are exceptionally rare as acquired resistance mechanisms. We utilized next-generation sequencing (NGS) to identify a rare ROS1 intragenic rearrangement (exons 35–37) in three never-smoking women with EGFR-mutant lung adenocarcinoma following progression on EGFR TKIs. Clinical courses were heterogeneous: one patient achieved a durable partial response using combined osimertinib and crizotinib. A second patient, intolerant to dual TKI therapy due to QTc prolongation and grade 3 edemas, achieved a sustained partial response with platinum-pemetrexed chemotherapy. The third patient exhibited polyclonal resistance, including EGFR C797S and TP53 mutations, with fatal central nervous system progression. In this three-patient case series, ROS1 exon 35–37 RNA-level intragenic rearrangements were repeatedly detected after EGFR-TKI progression, suggesting a rare transcript-level alteration within heterogeneous resistance evolution. However, its biological significance, driver versus passenger role, and therapeutic relevance remain uncertain. Combined EGFR and ROS1 inhibition may be considered in selected cases, but further validation is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
- Molecular Diagnosis Laboratory, Department of Pathology, National Cheng Kung University Hospital, Tainan 704, Taiwan.
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Zitieren
APA
Liu, P. T., Chen, Y. L., Chen, W. L., Ho, C. L., & Lee, C. H. (2026). Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Series. Current Oncology, 33(6), 311. https://doi.org/10.3390/curroncol33060311
Vancouver
Liu PT, Chen YL, Chen WL, Ho CL, Lee CH. Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Series. Current Oncology. 2026;33(6):311. doi:10.3390/curroncol33060311
BibTeX
@article{Liu2026,
author = {Liu, Po-Tsen and Chen, Yi-Lin and Chen, Wan-Li and Ho, Chung-Liang and Lee, Chun-Hui},
title = {Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Series},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {6},
pages = {311},
doi = {10.3390/curroncol33060311}
}
EUVIMED